<DOC>
<DOCNO>EP-0626967</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PROCESS FOR PREPARING ENANTIOMERICALLY PURE FLUORINATED EPOXYCHROMANS
</INVENTION-TITLE>
<CLASSIFICATIONS>C07B5300	C07D30700	C07D30732	C07D49310	C07D30304	C07D491044	C07D49100	C07D49300	B01J3118	B01J3116	C07D30314	C07D49304	C07D30300	C07F1300	C07F1300	C07B5300	B01J3122	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07B	C07D	C07D	C07D	C07D	C07D	C07D	C07D	B01J	B01J	C07D	C07D	C07D	C07F	C07F	C07B	B01J	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07B53	C07D307	C07D307	C07D493	C07D303	C07D491	C07D491	C07D493	B01J31	B01J31	C07D303	C07D493	C07D303	C07F13	C07F13	C07B53	B01J31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A process for preparing compounds of formula (B) wherein: one of A1' or A2' represents hydrogen and the other represents a group CF3-Y- wherein Y represents -CF2-, 
>
 C=O, or -CH(OH)-, or A1' and A2' are groups convertible to A1 and A2 respectively. Y1 represents -O-, -CH2- or NR
<
O
>
 wherein R
<
O
>
 is hydrogen, alkyl or alkylcarbonyl; R1 and R2 independently represent hydrogen or alkyl; or R1 and R2 together represent a C2-7 polymethylene moiety; R3 represents hydrogen, hydroxy, alkoxy or acyloxy and R4 is hydrogen or R3 and R4 together represent a bond; which process comprises reacting a compound of formula (C): wherein the variable A1', A2', Y1, R1 and R2 are as defined above, in the presence of an oxygen source and a chiral catalyst as defined in WO/91/14694.
 
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
This invention relates to a novel process for preparing certain epoxides.EP-A-0 376 524 describes certain compounds of formula (A):

or, where appropriate, a pharmaceutically acceptable salt thereof, or a
pharmaceutically acceptable solvate thereof
wherein:
one of A1 or A2 represents hydrogen and the other represents a group
CF3-Y- wherein Y represents -CF2-, >C=O, or -CH(OH)-;Y1 represents -O-, -CH2- or NR0 wherein R0 is hydrogen, alkyl or
alkylcarbonyl;R1 and R2 independently represent hydrogen or alkyl; orR1 and R2 together represent a C2-7 polymethylene moiety;R3 represents hydrogen, hydroxy, alkoxy or acyloxy and R4 is hydrogen or
R3 and R4 together represent a bond;R5 represents either a moiety of formula (a):

wherein A represents >C=X wherein X is O, S or NR8 wherein R8
represents CN, NO2, COR9 wherein R9 is alkyl, amino, monoalkylamino,
fluoroalkyl, phenyl or substituted phenyl or R8 is SO2R9 wherein R9 is as
defined above, or A represents a bond;
when A represents >C=X wherein X is O or S, then R6 is hydrogen; alkyl
optionally substituted by one or more groups or atoms selected from
halogen, hydroxy, alkoxy, alkoxycarbonyl, carboxy or an ester or amide 
thereof, amino, monoalkylamino or dialkylamino; alkenyl; amino
optionally substituted by an alkyl or alkenyl group or by an alkanoyl
group optionally substituted by up to three halo atoms, by a phenyl group
optionally substituted by alkyl, alkoxy or halogen; substituted or
unsubstituted aryl or substituted or unsubstituted heteroaryl; and R7
represents hydrogen or alkyl;or R6 and R7 together represent a linking chain of formula -A3-A4-, A3
being attached to the nitrogen atom of the moiety -N-A- and A4 being
attached to the group A on the said moiety, and wherein A3 represents a
substituted or unsubstituted methylene group, A4 represents 2 or 3
linking members, one of the linking members optionally representing O, S
or NR and the other linking members each independently representing a
substituted or unsubstituted methylene group;R represents hydrogen, alkyl, alkanoyl, phenyl C1-4- alkyl, arylcarbonyl
wherein the aryl group may be substituted or unsubstituted; or R is mono-
or bi-cyclic- heteroarylcarbonyl;when A represents >C=X wherein X represents NR8, then R6 represents
-NH.R10 wherein R10 is hydrogen, alkyl, C3-6 cycloalkyl, alkenyl or
alkynyl and R7 is hydrogen or alkyl; or R7 and R10 together represent C2-4
polymethylene;when A represents a bond, then R6 and R7 together with the nitrogen
atom to which they are attached, form an unsaturated
</DESCRIPTION>
<CLAIMS>
A process for preparing compounds of formula (B)


wherein:

one of A
1
' or A
2
' represents hydrogen and the other represents a group CF
3
-Y- wherein
Y represents -CF
2
-, 
>
C=O, or -CH(OH)-;
Y
1
 represents -O-, -CH
2
- or NR
0
 wherein R
0
 is hydrogen, alkyl or alkylcarbonyl; R
1
 and
R
2
 independently represent hydrogen or alkyl; or R
1
 and R
2
 together represent a C
2-7

polymethylene moiety;

which process comprises reacting a compound of formula (C):


wherein the variables A
1
', A
2
', Y
1
, R
1
 and R
2
 are as defined above, in the presence of an
oxygen source and a chiral catalyst is of formula (E):



wherein Z
1
 and Z
4
 are the same and are selected from the group consisting of methyl, 
t
-butyl
or methoxy and Q
2
 and Q
3
 are either both phenyl or together with the carbon atoms
to which they are attached form a hexyl ring. 
A process according to claim 1 wherein in the compound of formula (B) A
1
' is
CF
3
CF
2
, A
2
' is hydrogen, Y
1
 is oxygen and R
1
 and R
2
 are both methyl.
A process according to claim 1 or 2 wherein the compound of formula (B) is
3S,4S-2,2-dimethyl-3,4-epoxy-6-pentafluoroethyl-2H-1-benzopyran.
A process according to claim 1 wherein Z
1
 and Z
4
 are both 
t
-butyl and Q
2
 and
Q
3
 together with the carbon atom to which they are attached form a hexyl group.
A process according to claim 4 wherein the chiral catalyst is (S,S)-[1,2-bis(3,5-di-tert-butylsalicylideneamino)cyclohexane]manganese

(III) chloride.
A process for preparing compounds of formula (A)


or, where appropriate, a pharmaceutically acceptable salt thereof, or a pharmaceutically
acceptable solvate thereof

wherein:

one of A
1
 or A
2
 represents hydrogen and the other represents a group CF
3
-Y- wherein Y
represents -CF
2
-, 
>
C=O, or -CH(OH)-;
Y
1
 represents -O-, -CH
2
- or NR
0
 wherein R
0
 is hydrogen, alkyl or alkylcarbonyl; R
1
 and
R
2
 independently represent hydrogen or alkyl; or R
1
 and R
2
 together represent a C
2-7

polymethylene moiety;
R
3
 represents hydrogen, hydroxy, alkoxy or acyloxy and R
4
 is hydrogen or R
3
 and R
4

together represent a bond;
R
5
 represents a moiety of formula (a): 


wherein A represents 
>
C=X wherein X is O or S, or A represents a bond;
when A represents 
>
C=X wherein X is O or S, then R
6
 and R
7
 together represent a
linking chain of formula -A
3
-A
4
-, A
3
 being attached to the nitrogen atom of the moiety
-N-A- and A
4
 being attached to the group A on the said moiety, and wherein A
3

represents a substituted or unsubstituted methylene group, A
4
 represents 2 or 3 linking
members, one of the linking members optionally representing O, S or NR and the other

linking members each independently representing a substituted or unsubstituted
methylene group;
R represents hydrogen, alkyl, alkanoyl, phenyl C
1-4
- alkyl, arylcarbonyl wherein the aryl
group may be substituted or unsubstituted; or R is mono- or bi-cyclic- heteroarylcarbonyl;

;
when A represents a bond, then R
6
 and R
7
 together with the nitrogen atom to which they
are attached, form an unsaturated heterocyclic ring having 5 to 7 ring atoms, which ring

atoms comprise up to 2 further nitrogen atoms and a carbon atom, the carbon atom being
substituted with either an oxo group or a thioxo group, the remaining ring atoms being

substituted or unsubstituted;

which comprises preparing a compound of formula (B), as defined in claim 1, according
to the process of claim 1 and thereafter preparing a compound of formula (A) or, where

appropriate a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable
solvate thereof.
A process according to claim 6 in which the compound of formula (A) is
(3S,4R)-3,4-dihydro-2,2-dimethyl-4-(2-oxopiperidin-1-yl)-6-penta-fluoroethyl-2H-1-benzopyran-3-ol.
</CLAIMS>
</TEXT>
</DOC>
